Jianwen Li

Title: The Innovations of Jianwen Li

Introduction

Jianwen Li is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of monoclonal antibodies. His work focuses on enhancing the stability and efficacy of these important therapeutic agents.

Latest Patents

Jianwen Li holds a patent for a pharmaceutical composition of a humanized monoclonal anti-PD-L1 antibody. This invention is crucial in the realm of antibody formulations, as it comprises 1-150 mg/ml of the humanized monoclonal anti-PD-L1 antibody, a buffer at 3-50 mM, 2-150 mg/ml of an isotonic adjuster/stabilizer, and 0.01-0.8 mg/ml of a surfactant. The pH of the formulation is maintained at about 4.5-6.8. This innovative composition prevents the increase of antibody aggregates while ensuring the long-term maintenance of the biological binding activity of the antibody.

Career Highlights

Throughout his career, Jianwen Li has worked with prominent companies in the pharmaceutical industry, including Nanjing Shunxin Pharmaceutical Co., Ltd. and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. His experience in these organizations has allowed him to refine his expertise in drug formulation and development.

Collaborations

Jianwen Li has collaborated with several professionals in his field, including Yanju Cheng and Yingchun Li. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Jianwen Li's contributions to the field of pharmaceutical compositions, particularly in monoclonal antibodies, highlight his innovative spirit and dedication to improving therapeutic options. His work continues to influence the pharmaceutical industry and offers promising advancements in antibody formulations.